Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

Trends in Neurosciences

Volumn 33, Issue 3, 2010, Pages 140-152

  Aktas, Orhan ^a   Kieseier, Bernd ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMILORIDE; BETA1A INTERFERON; CLADRIBINE; CYTOKINE; DACLIZUMAB; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE; INTERLEUKIN 2 RECEPTOR; LAMOTRIGINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PLACEBO; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RITUXIMAB; ROQUINIMEX; TERIFLUNOMIDE; TOPIRAMATE; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE LEUKEMIA; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENCEPHALITIS; ENERGY METABOLISM; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE MIGRATION INHIBITION; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; ENCEPHALITIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MODELS, ANIMAL; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROPROTECTIVE AGENTS;

EID: 77649290565     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2009.12.002     Document Type: Review

References (133)

1. Menge T., et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 68 (2008) 2445-2468
2. Hartung H.P., and Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann. Neurol. 66 (2009) 429-432
3. Rudick R.A., and Polman C.H. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 8 (2009) 545-559
4. Hartung H.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
5. Trapp B.D., and Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 31 (2008) 247-269
6. Steinman L. Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. J. Exp. Med. 197 (2003) 1065-1071
7. Gold R., et al. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
8. Ransohoff R.M. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol. 27 (2006) 167-168
9. Giovannoni, G. (2009) Results from the CLARITY study: a phase III, randomized, double-blind study to evaluate the safety and efficacy of oral cladribine in relapsing-remitting multiple sclerosis (RRMS). Annual Meeting of the American Academy of Neurology, Seattle, WA, USA. Neurology Abstract LBS.001
10. Hartung, H.P. et al. Development of oral cladribine for the treatment of multiple sclerosis. J. Neurol.(in press), Epub (Nov 18)
11. Merrill J.E., et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti at model of experimental autoimmune encephalomyelitis. J. Neurol. 256 (2009) 89-103
12. Nguyen T., et al. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284 (2009) 13291-13295
13. Kappos L., et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372 (2008) 1463-1472
14. Comi G., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371 (2008) 2085-2092
15. Aktas O., et al. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J. Neuroimmunol. 184 (2007) 17-26
16. Dustin M.L. The cellular context of T cell signaling. Immunity 30 (2009) 482-492
17. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
18. Lutterotti A., and Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 7 (2008) 538-547
19. Waldmann H., and Hale G. CAMPATH: from concept to clinic. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360 (2005) 1707-1711
20. Coles A.J., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46 (1999) 296-304
21. Coles A.J., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359 (2008) 1786-1801
22. Rose J.W., et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69 (2007) 785-789
23. Montalban, X. et al. (2007) Preliminary CHOICE results: a phase 2, randomised, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic. Mult. Scler. 13, S18
24. Racke M.K. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 21 Suppl. 1 (2008) S9-S18
25. Linington C., et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130 (1988) 443-454
26. Mathey E.K., et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 204 (2007) 2363-2372
27. Huizinga R., et al. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J. Neuropathol. Exp. Neurol. 66 (2007) 295-304
28. Franciotta D., et al. B cells and multiple sclerosis. Lancet Neurol. 7 (2008) 852-858
29. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
30. Hawker K., et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66 (2009) 460-471
31. Bartholomaus I., et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462 (2009) 94-98
32. Bechmann I., et al. What is the blood-brain barrier (not)?. Trends Immunol. 28 (2007) 5-11
33. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
34. Mullershausen F., et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 5 (2009) 428-434
35. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 158 (2009) 1173-1182
36. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115 (2007) 84-105
37. Miron V.E., et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 63 (2008) 61-71
38. Kappos L., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (2006) 1124-1140
39. O'Connor P., et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72 (2009) 73-79
40. Cohen, J. et al. (2010) Oral Fingolimod vs intramuscular interferon in relapsing multiple sclerosis, New Engl J Med, E-pub (Jan 20)
41. Leypoldt F., et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 72 (2009) 1022-1024
42. Schulze-Topphoff U., et al. Roles of the kallikrein/kinin system in the adaptive immune system. Int. Immunopharmacol. 8 (2008) 155-160
43. Schulze-Topphoff U., et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med. 15 (2009) 788-793
44. Platten M., et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14948-14953
45. Stegbauer J., et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14942-14947
46. Ferguson B., et al. Axonal damage in acute multiple sclerosis lesions. Brain 120 (1997) 393-399
47. Trapp B.D., et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
48. Diestel A., et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J. Exp. Med. 198 (2003) 1729-1740
49. Giuliani F., et al. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171 (2003) 368-379
50. Aktas O., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46 (2005) 421-432
51. Nitsch R., et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 24 (2004) 2458-2464
52. Sobottka B., et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am. J. Pathol. 175 (2009) 1160-1166
53. Gobel, K. et al. Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyte-directed CD8(+) T cell attack. Glia. (in press), Epub (Sept 24)
54. Friese M.A., and Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 66 (2009) 132-141
55. Peterson J.W., et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
56. Kutzelnigg A., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
57. Frohman E.M., et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol. 62 (2005) 1345-1356
58. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 65 (2009) 239-248
59. Frischer J.M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132 (2009) 1175-1189
60. Nave K.A., and Trapp B.D. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci. 31 (2008) 535-561
61. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis - current status. Nat. Clin. Pract. Neurol. 4 (2008) 159-169
62. Kapoor R., et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann. Neurol. 53 (2003) 174-180
63. Craner M.J., et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8168-8173
64. Werner P., et al. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 50 (2001) 169-180
65. Dutta R., et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006) 478-489
66. Mahad D.J., et al. Mitochondrial changes within axons in multiple sclerosis. Brain 132 (2009) 1161-1174
67. Filippi M., et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126 (2003) 433-437
68. Cader S., et al. Discordant white matter N-acetylaspartate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage 36 (2007) 19-27
69. Craner M.J., et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49 (2005) 220-229
70. Black J.A., et al. Sodium channel activity modulates multiple functions in microglia. Glia 57 (2009) 1072-1081
71. Black J.A., et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 62 (2007) 21-33
72. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
73. Meuth S.G., et al. TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J. Biol. Chem. 283 (2008) 14559-14570
74. Friese M.A., et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med. 13 (2007) 1483-1489
75. Franklin R.J., and Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 9 (2008) 839-855
76. Patani R., et al. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol. Appl. Neurobiol. 33 (2007) 277-287
77. Kuhlmann T., et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131 (2008) 1749-1758
78. Chang A., et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346 (2002) 165-173
79. Shen S., et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 11 (2008) 1024-1034
80. Mi S., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13 (2007) 1228-1233
81. John G.R., et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 8 (2002) 1115-1121
82. Jurynczyk M., et al. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J. Neuroimmunol. 170 (2005) 3-10
83. Kremer D., et al. p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 9087-9092
84. Schnell L., and Schwab M.E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343 (1990) 269-272
85. Karnezis T., et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat. Neurosci. 7 (2004) 736-744
86. Fontoura P., and Steinman L. Nogo in multiple sclerosis: growing roles of a growth inhibitor. J. Neurol. Sci. 245 (2006) 201-210
87. Hermanns S., et al. The collagenous wound healing scar in the injured central nervous system inhibits axonal regeneration. Adv. Exp. Med. Biol. 557 (2006) 177-190
88. Nait-Oumesmar B., et al. Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4694-4699
89. Chang A., et al. Neurogenesis in the chronic lesions of multiple sclerosis. Brain 131 (2008) 2366-2375
90. Wang Y., et al. Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis. Ann. Neurol. 64 (2008) 417-427
91. Wang D., et al. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia 51 (2005) 235-240
92. Luo J., et al. Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest. 117 (2007) 3306-3315
93. Ridet J.L., et al. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20 (1997) 570-577
94. Sofroniew M.V. Reactive astrocytes in neural repair and protection. Neuroscientist 11 (2005) 400-407
95. Studer L., et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J. Neurosci. 20 (2000) 7377-7383
96. Smith J., et al. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10032-10037
97. Prozorovski T., et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell Biol. 10 (2008) 385-394
98. Zipp F., and Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 29 (2006) 518-527
99. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
100. Rudick R.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 911-923
101. Yousry T.A., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354 (2006) 924-933
102. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 8 (2009) 28-31
103. Hemmer B., et al. Central nervous system infections - a potential complication of systemic immunotherapy. Curr. Opin. Neurol. 19 (2006) 271-276
104. Berger J.R., and Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 65 (2009) 367-377
105. Verbeeck J., et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut 57 (2008) 1393-1397
106. Stuve O., et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63 (2006) 1383-1387
107. Ransohoff R.M. "Thinking without thinking" about natalizumab and PML. J. Neurol. Sci. 259 (2007) 50-52
108. Krumbholz M., et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71 (2008) 1350-1354
109. Zohren F., et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111 (2008) 3893-3895
110. Lindberg R.L., et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J. Neuroimmunol. 194 (2008) 153-164
111. Sunyaev S.R., et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 5 (2009) e1000368
112. Thompson, S.A. et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. (in press), Epub (Sep 10)
113. Bloom D., et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am. J. Transplant. 9 (2009) 1835-1845
114. Cox A.L., et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35 (2005) 3332-3342
115. Bielekova B., et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5941-5946
116. Castillo J., et al. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 18 (2009) 491-500
117. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr. Opin. Investig. Drugs 9 (2008) 1206-1215
118. Bechtold D.A., et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol. 253 (2006) 1542-1551
119. Lucchinetti C.F., et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 6 (1996) 259-274
120. Lucchinetti C.F., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 (2002) 1450-1461
121. Lennon V.A., et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005) 473-477
122. Tait M.J., et al. Water movements in the brain: role of aquaporins. Trends Neurosci. 31 (2008) 37-43
123. Aktas O., and Hartung H.P. Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. J. Neurol. 256 (2009) 1906-1908
124. Bradl M., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66 (2009) 630-643
125. Barnett M.H., et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann. Neurol. 65 (2009) 32-46
126. Breij E.C., et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 63 (2008) 16-25
127. Vogt J., et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann. Neurol. 66 (2009) 310-322
128. Schirmer L., et al. Substantial early, but nonprogressive neuronal loss in multiple sclerosis (ms) spinal cord. Ann. Neurol. 66 (2009) 698-704
129. Steinman L., and Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26 (2005) 565-571
130. Kornek B., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157 (2000) 267-276
131. Derfuss T., et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 8302-7
132. Krishnamoorthy G., et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 15 (2009) 626-632
133. Morgen K., et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 30 (2006) 891-898